CardioFit™ for the Treatment of Heart Failure

BioControl Medical

Status and phase

Completed

Phase 2

Conditions

Heart Failure

Treatments

Procedure: Implantation and activation of the vagus nerve stimulator

Study type

Interventional

Funder types

Industry

Identifiers

NCT00461019

CF-MS-01

Details and patient eligibility

About

Congestive Heart Failure is the result of a number of diseases affecting the heart, causing the heart's failure to properly meet the body demands for blood circulation. In spite of advances in drug therapy, it remains a significant public health problem.

Pharmacologic antagonism of the beta-adrenergic receptors shifting the autonomic balance in the direction of greater vagal influence is a well-proven treatment for heart failure patients, although there are patients who cannot tolerate, or only partially benefit from such a treatment.

It has been proven in the past and well established that parasympathetic nerve stimulation can slow the rate of the heart and reduce the workload of the heart. Therefore, the potential benefit of vagus nerve stimulation, hence parasympathetic activation, for treatment of heart failure is substantial.

In this study, the safety and efficacy of a new vagus nerve stimulating system will be evaluated. This study will compare whether the new device improves Heart Failure parameters in Class II - III Heart Failure patients.

Full description

Purpose of the study: To determine the safety and efficacy of the CardioFit™ system for treatment of Class II-III Heart Failure patients.
Study hypothesis: CardioFit system treatment will improve patients Heart Failure parameters.
Tested hypothesis: Thirty patients are required to provide 80% power at 95% confidence level in order to detect 12 points difference on a quality of life questionnaire between pre- and post activation.
Design: Prospective, self-controlled interventional study composed of 5 periods: Pre-implantation, Implantation, Device activation, Follow-up (with active device) and post-study extension period.
Study duration is 7.5-months per patient. At the end of the study, patients enter an extension period (with active devices) during which they will be monitored for quality of life and survival, for up to 3 years post-implantation in 6-months intervals.
Study Endpoints:
- Primary endpoints: The occurrence of all system and/or procedure related adverse events.
- Secondary endpoints: changes in the following individual variables as well as in a composite score of individual variables change: NYHA class; Quality of Life; Exercise capacity (by 6-min walk); LV Ejection fraction; LV end-systolic and end-diastolic volumes; blood tests.
Up to 10 participating centers in Europe, Israel and Australia

Enrollment

32 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The patient is in chronic heart failure, NYHA II-III. The patient may have been previously in class IV but must be in class II or III for three or more months prior to study entry;
Age between 18 and 75 years;
The patient is a male or postmenopausal female. Females of childbearing age may be included if pregnancy is excluded and acceptable contraception measures are used;
Patient must sign an approved informed consent form. Patient agrees to attend all follow-up evaluations;
Patient should be in sinus rhythm. Average 24-hour heart rate is between 60 and 110 b/min in a recorded 24-h Holter measurement;
Patient should be in optimal medical treatment with no change in treatment in the previous 3 months with the exception of diuretics;
Left ventricular ejection fraction estimated by echocardiography, cardiac angiography, radionuclide study, or other accepted mode of evaluation, is no more than 35%;
Patient is physically capable and willing to perform repeated physically demanding tests associated with the study.

Exclusion criteria

Presence of an immediately life threatening condition or disease other than heart failure, such as cancer, terminal renal failure etc.
Acute myocardial Infarction (MI), variant angina pectoris, unstable angina or acute coronary syndrome in the previous three months;
Previous stroke;
Coronary Artery Bypass Surgery (CABG) or Percutaneous Coronary Intervention in the past 3 months;
Episode of NYHA class IV heart failure, including acute pulmonary oedema in the previous three months;
Heart failure due to acute myocarditis. Restrictive or constrictive pericarditis, haemodynamically significant aortic valve insufficiency aortic stenosis, or mitral valve stenosis;
Severe renal or hepatic failure (Creatinine level>3 mg% (265 micromole/liter) or transaminase level four times ULN);
Diabetes Mellitus treated with insulin for more than two years prior to study entry;
Diabetic neuropathy;
Previous neck surgery, including for Peripheral Vascular Disease (PVD), malignancy, and previous irradiation therapy of the neck;
Current hypotension (systolic blood pressure below 80 mmHg);
Active peptic disease or history of upper GI bleeding;
Asthma, severe COPD (e.g. FEV1<1.5 liter), or severe restrictive lung disease;
1st degree AV block with PR interval > 240msec, 2nd or 3rd degree AV block;
Atrial fibrillation or flutter in the in the previous 3 months;
Sustained ventricular tachyarrhythmia with hemodynamic compromise, in the absence of implanted ICD;
Long QT syndrome, congenital or acquired;
Recorded or suspected symptomatic vaso-vagal response;
Treatment by investigational drug or device within the past 3 months;
Glaucoma, or history of glaucoma;
Major psychiatric disorder in the present or in the past; Dementia;
Patients transplanted with tissues or organs;
Immunosuppressed patients; patients under systemic steroid treatment;
Anemia with Hb<10gr/L, unless treated with Epo;
Patients who are at risk for carotid arteries plaques and have unstable carotid plaques, as assessed by Echo Doppler; and/or patients with >70% carotid artery stenosis;
Patient is candidate for cardiac resynchronization device implantation.